Januritin ES Tablet 100 mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.
MFDS item code 201502304 · Approved 2015.04.16
This product's status changed to Expired on 2025.04.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to improve blood sugar control in patients with type 2 diabetes. It may be initiated as monotherapy but can be used with metformin if blood sugar control is difficult in patients who have not previously received diabetes medication. This drug can also be administered to enhance the effectiveness when adequate control cannot be achieved with monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin. It is added in combination therapy when difficulties with blood sugar control are present. This versatility helps to improve blood sugar control.
This medicine is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. (See Precautions for Use, 5. General Precautions.) Patients with renal impairment As dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may rarely cause severe allergic reactions after administration. If symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a physician. Acute pancreatitis may occur during treatment with this medication, so notify healthcare personnel immediately if symptoms such as abdominal pain, nausea, or vomiting arise. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in patients who are allergic to this medication or its components. Patients with impaired kidney function may need dose adjustments and should undergo regular kidney function tests. This medication may be used alone or in conjunction with other diabetes treatments, but caution is advised as the risk of hypoglycemia may increase when used with insulin or sulfonylureas. During treatment, symptoms such as headache, upper respiratory infection, nasopharyngitis, dyspepsia, diarrhea, and muscle aches may occur; if these persist or worsen, consult a physician. This medication is not recommended for use in pregnant or breastfeeding women, nor in children and adolescents under 18 years old, as safety and efficacy have not been established. Due to the potential for decreased renal function in older adults, dose adjustments and monitoring of kidney function are necessary. In case of overdose, seek medical attention immediately for appropriate treatment, as some may be removed by dialysis. If skin blisters or soreness occur during treatment, consult a physician immediately for treatment, and consider stopping the medication if severe or persistent joint pain occurs. There is a possibility of drug interactions when taken with other medications, so always inform healthcare personnel about other medications being taken, especially when used with cyclosporine or digoxin, as caution is needed.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering, at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and prevent degradation.
Beige colored, round, biconvex film-coated tablet
28 tablets/box [(14 tablets/PTPX2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.